Impact of Luspatercept on Healthcare Resource Use (HCRU) Among Patients with Lower-Risk, Myelodysplastic Syndromes (LR-MDS): A Medical Record Review in Canada, Germany, and Spain
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-206948
Abstract: Background: In patients with lower-risk myelodysplastic syndrome (LR-MDS), luspatercept has demonstrated significant clinical benefit. However, luspatercept's impact on healthcare resource use (HCRU) is not well documented. This study aimed to describe MDS-related HCRU in patients… read more here.
Keywords: index period; luspatercept therapy; hcru; index ... See more keywords